Urology

Urovant Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Sumitovant Biopharma Announces Urovant Sciences Collaboration with Sunovion Pharmaceuticals

Lead Product(s): Vibegron

Therapeutic Area: Urology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Sumitovant Biopharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 19, 2020

Details:

The exclusive three-year distribution agreement with aims to support the commercialization of vibegron, an investigational agent for the treatment of overactive bladder.

Astellas Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

FDA Approves VESIcare LS™ (solifenacin succinate) Oral Suspension for Pediatric Patients

Lead Product(s): Solifenacin Succinate

Therapeutic Area: Urology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 27, 2020

Details:

VESIcare LS is an oral suspension dosage form that was specifically developed to facilitate dosing and administration in the pediatric population.

Sumitovant Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Sumitovant Biopharma's Family of Companies Achieve Multiple Clinical and Corporate Milestones

Lead Product(s): Vibegron,Tolterodine Tartrate

Therapeutic Area: Urology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 21, 2020

Details:

Urovant Sciences a family company of Sumitovant announced the publication of the safety and efficacy results of URO-902 in female patients with overactive bladder from two Phase 1 trials.

Urovant Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Urovant Sciences Presents Clinical Efficacy & Safety Data on Lead Drug Candidate Vibegron at American Urological Association Annual Meeting

Lead Product(s): Vibegron

Therapeutic Area: Urology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 14, 2020

Details:

52-week post hoc analysis shows Vibegron patients had statistically significant, sustained reduction in UUI and total incontinence episodes compared to active control.

Urovant Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial Results

Lead Product(s): Vibegron

Therapeutic Area: Urology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 02, 2020

Details:

The double-blind, placebo-controlled 12-week trial, in patients with OAB, studied vibegron 75 mg once-daily compared to placebo and included an active control.

Urovant Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Urovant Sciences Announces Results from URO-902 Phase 1 Trials

Lead Product(s): URO-902

Therapeutic Area: Urology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 04, 2020

Details:

In the trials, URO-902 was well tolerated and the administration via direct injection procedure demonstrated statistically significant improvement in OAB symptoms.

Find

Find Urology Clinical Drug Pipeline Developments & Deals

Product Type

Development Status

Urovant Sciences

Sumitovant Biopharma Announces Urovant Sciences Collaboration with Sunovion Pharmaceuticals

Astellas Pharma

FDA Approves VESIcare LS™ (solifenacin succinate) Oral Suspension for Pediatric Patients

Sumitovant Biopharma

Sumitovant Biopharma's Family of Companies Achieve Multiple Clinical and Corporate Milestones

Urovant Sciences

Urovant Sciences Presents Clinical Efficacy & Safety Data on Lead Drug Candidate Vibegron at American Urological Association Annual Meeting

Urovant Sciences

Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial Results

Urovant Sciences

Urovant Sciences Announces Results from URO-902 Phase 1 Trials